%0 Journal Article
%T CD26: A prognostic marker of other systemic malignancies besides colo-rectal carcinomas
%A Shailendra Kapoor
%J World Journal of Clinical Oncology
%D 2012
%I Baishideng Publishing Group Co. Limited
%R 10.5306/wjco.v3.i8.126
%X I read with great interest the recent article by Cordero et al in a recent issue of your esteemed journal. Interestingly, the past few years have seen the emergence of CD26 as an important diagnostic and prognostic marker for a number of systemic malignancies besides colo-rectal carcinomas. For instance, serum CD26 levels are an important emerging marker of B-cell chronic lymphocytic leukemia (B-CLL). In fact, Molica et al have recently reported shorter time to first treatment in B-CLL which exhibit higher serum CD26 levels and simultaneously demonstrate absence of mutation in IgV (H). Similarly, CD26 serves as a marker of poor prognosis in T cell lymphomas. Simultaneously, a poor response to 2กฏ-deoxycoformycin is seen T cell lymphomas expressing CD26. Similarly, breast carcinomas exhibit decreased CD26 mean fluorescence intensity and a decreased percentage of CD26 positive lymphocytes in comparison to benign breast tumors and healthy individuals.
%K CD26
%K Cancer
%K Carcinogenesis
%K Colon cancer
%K Marker
%U http://www.wjgnet.com/2218-4333/full/v3/i8/126.htm